Cipla Inc

HIV-AIDS

For over two decades, we stood by our motto, “None shall be denied” and have been committed to the cause of HIV/AIDS. In our crusade against the disease, we have developed over 15 single and combination medicines that revolutionized HIV therapy, not just in India but across the world. Our world class scientific resources and educational platforms help physicians across the world manage the disease effectively. Our fight against HIV/ AIDS has increased accessibility worldwide. And with our continued commitment to research and development the world can look forward to further progress in our fight against HIV/ AIDS.

In 2001, we introduced the world’s first ever recommended 3-in-1 fixed dose combination (Stavudine + Lamivudine + Nevirapine) to fight AIDS. It was made available at less than $1 per day compared to over $12,000 per patient per year prevailing in most countries throughout the world. It lifted the death sentence from millions across the developing world. We have also done pioneering work in paediatric HIV and addressed the needs of every kind of HIV patient, from pregnant mothers to babies and from children to adults. It’s not surprising that today around 1 million patients in the world are on our Antiretrovirals, and with regular therapy they can live for years and lead a near normal life.